

Liwu Fu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/858891/publications.pdf>

Version: 2024-02-01

80
papers

3,857
citations

156536

32
h-index

150775

59
g-index

84
all docs

84
docs citations

84
times ranked

6387
citing authors

#	ARTICLE	IF	CITATIONS
1	Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 636-649.	2.0	9
2	Clinical significance of FBXW7 loss of function in human cancers. <i>Molecular Cancer</i> , 2022, 21, 87.	7.9	47
3	Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 89.	7.1	2
4	The prospects of tumor chemosensitivity testing at the single-cell level. <i>Drug Resistance Updates</i> , 2021, 54, 100741.	6.5	4
5	PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3120-3133.	5.7	16
6	Aldehyde Dehydrogenase 2 Mediates Alcohol-induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression. <i>Advanced Science</i> , 2021, 8, 2003404.	5.6	25
7	The key roles of cancer stem cell-derived extracellular vesicles. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 109.	7.1	64
8	GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma. <i>Molecular Cancer</i> , 2021, 20, 80.	7.9	17
9	The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1400-1411.	5.7	69
10	Mutasynthesis of Antibacterial Halogenated Actinomycin Analogues. <i>Journal of Natural Products</i> , 2021, 84, 2217-2225.	1.5	6
11	Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. <i>Molecular Cancer</i> , 2021, 20, 17.	7.9	67
12	KRAS mutation: from undruggable to druggable in cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 386.	7.1	255
13	Editorial of special issue on pharmacotherapeutics of digestive tumors. <i>Gastroenterology Report</i> , 2020, 8, 177-178.	0.6	1
14	Culture and application of conditionally reprogrammed primary tumor cells. <i>Gastroenterology Report</i> , 2020, 8, 224-233.	0.6	5
15	Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 141.	7.1	34
16	Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. <i>Molecular Cancer</i> , 2020, 19, 139.	7.9	17
17	The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. <i>Molecular Cancer</i> , 2020, 19, 81.	7.9	82
18	Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. <i>Molecular Cancer</i> , 2020, 19, 58.	7.9	124

#	ARTICLE	IF	CITATIONS
19	Reversal of ABCB1-related multidrug resistance by ERK5-IN-1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 50.	3.5	14
20	p38 ^{Î³} MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis. <i>Cancer Research</i> , 2020, 80, 3251-3264.	0.4	47
21	CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 100-110.	2.0	9
22	Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 799-811.	5.7	19
23	Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 588641.	1.3	6
24	Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo. <i>Cell Communication and Signaling</i> , 2019, 17, 110.	2.7	8
25	MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC. <i>Molecular Cancer</i> , 2019, 18, 93.	7.9	16
26	A panel of three plasma microRNAs for colorectal cancer diagnosis. <i>Cancer Epidemiology</i> , 2019, 60, 67-76.	0.8	33
27	Progress in understanding mitochondrial calcium uniporter complex-mediated calcium signalling: A potential target for cancer treatment. <i>British Journal of Pharmacology</i> , 2019, 176, 1190-1205.	2.7	43
28	Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance. <i>Molecular Cancer</i> , 2019, 18, 182.	7.9	44
29	Secalonic acid D induces cell apoptosis in both sensitive and ABCG2-overexpressing multidrug resistant cancer cells through upregulating c-Jun expression. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 516-525.	5.7	17
30	Circulating Plasma miRNAs as Potential Biomarkers of Non-Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 327-336.	1.1	18
31	Benzothiazine based acetohydrazides and acetamides as anticancer agents. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2019, 32, 2795-2800.	0.2	1
32	PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis. <i>Biochemical Pharmacology</i> , 2018, 150, 131-140.	2.0	8
33	Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 31.	3.5	22
34	Increased Numb protein expression predicts poor clinical outcomes in esophageal squamous cell carcinoma patients. <i>Cancer Biology and Therapy</i> , 2018, 19, 34-41.	1.5	7
35	Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. <i>EBioMedicine</i> , 2018, 36, 553-562.	2.7	248
36	Olmudinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 in vitro and in vivo. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 563-574.	5.7	23

#	ARTICLE	IF	CITATIONS
37	Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR. <i>Cancer Research</i> , 2018, 78, 3532-3543.	0.4	23
38	Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. <i>Molecular Cancer</i> , 2018, 17, 25.	7.9	89
39	Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 2487-2499.	1.1	15
40	PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 2302-2317.	1.1	8
41	Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma. <i>Cancer Letters</i> , 2018, 432, 169-179.	3.2	35
42	Targeting Orai1-mediated store-operated Ca ²⁺ entry by a novel compound RP4010 for anti-proliferative activity against esophagus squamous cell carcinoma. <i>FASEB Journal</i> , 2018, 32, 750.38.	0.2	0
43	ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics. <i>Scientific Reports</i> , 2017, 7, 40064.	1.6	10
44	14-3-3 σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2. <i>Molecular Cancer Research</i> , 2017, 15, 418-428.	1.5	35
45	Establishment and characterization of arsenic trioxide resistant KB/ATO cells. <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 564-570.	5.7	14
46	Clinical Applications of Circulating Tumor Cells in Pharmacotherapy: Challenges and Perspectives. <i>Molecular Pharmacology</i> , 2017, 92, 232-239.	1.0	15
47	Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. <i>Experimental and Molecular Medicine</i> , 2017, 49, e303-e303.	3.2	37
48	Targeting calcium signaling in cancer therapy. <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 3-17.	5.7	428
49	Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	55
50	Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy. <i>Nature Communications</i> , 2017, 8, 1777.	5.8	146
51	Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2017, 124, 29-42.	2.0	37
52	Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma. <i>American Journal of Cancer Research</i> , 2017, 7, 203-217.	1.4	4
53	MAF1 suppresses AKT/mTOR signaling and liver cancer through activation of PTEN transcription. <i>Hepatology</i> , 2016, 63, 1928-1942.	3.6	61
54	Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells <i>In Vitro</i> , <i>In Vivo</i> , and <i>Ex Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1845-1858.	1.9	43

#	ARTICLE	IF	CITATIONS
55	Overcoming ABCG2-mediated multidrug resistance by a mineralized hyaluronan-drug nanocomplex. <i>Journal of Materials Chemistry B</i> , 2016, 4, 6652-6661.	2.9	4
56	Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1. <i>Molecular Therapy</i> , 2016, 24, 156-165.	3.7	35
57	The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutic drugs may finally work through immune response. <i>Oncotarget</i> , 2016, 7, 29794-29803.	0.8	48
58	The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. <i>Clinical Science</i> , 2015, 129, 809-822.	1.8	46
59	Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer. <i>British Journal of Pharmacology</i> , 2015, 172, 4089-4106.	2.7	31
60	Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 44643-44659.	0.8	39
61	Mechanisms of resistance to EGFR tyrosine kinase inhibitors. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 390-401.	5.7	383
62	Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. <i>Biochemical Pharmacology</i> , 2015, 97, 27-37.	2.0	41
63	Improving cell-based therapies by nanomodification. <i>Journal of Controlled Release</i> , 2015, 219, 560-575.	4.8	16
64	Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. <i>Oncotarget</i> , 2015, 6, 17738-17752.	0.8	17
65	Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells. <i>Oncotarget</i> , 2015, 6, 40850-40865.	0.8	11
66	Effect of HM910, a novel camptothecin derivative, on the inhibition of multiple myeloma cell growth <i>in vitro</i> and <i>in vivo</i> . <i>American Journal of Cancer Research</i> , 2015, 5, 1000-16.	1.4	5
67	Elevated Orai1 expression mediates tumor-promoting intracellular Ca ²⁺ oscillations in human esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2014, 5, 3455-3471.	0.8	125
68	Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E4504-12.	3.3	118
69	Synthesis and antiproliferative evaluation of novel tetrahydrobenzo[4,5-thieno[3,2:5,6]pyrido[4,3-d]pyrimidine derivatives. <i>RSC Advances</i> , 2014, 4, 29187-29192.	1.7	4
70	The tumor suppressive role of NUMB isoform 1 in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2014, 5, 5602-5614.	0.8	40
71	UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter. <i>American Journal of Cancer Research</i> , 2014, 4, 148-60.	1.4	6
72	Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. <i>Cancer Letters</i> , 2013, 328, 307-317.	3.2	106

#	ARTICLE	IF	CITATIONS
73	Synthesis and antitumor activity of novel quinazoline derivatives containing thiosemicarbazide moiety. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 925-930.	2.6	55
74	Synthesis and cytotoxicity of O,O'-dialkyl [2-(substituted phenoxy)acetamido](substituted) benzimidazole derivatives. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1018-1024.	2.6	18
75	Characterization of a stem cell population in lung cancer cell line GlcR82. <i>Thoracic Cancer</i> , 2012, 3, 8-18.	0.8	3
76	Synthesis and Biological Evaluation of Novel Phosphonates Derivatives of As Potential Antitumor Agents. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 2011, 186, 2096-2103.	0.8	10
77	Efficient synthesis and biological evaluation of 1,3-benzenedicarbonyl dithioureas. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1102-1104.	1.0	33
78	Synthesis and antitumor activity of ureas containing pyrimidinyl group. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 429-432.	2.6	27
79	A facile synthesis and biological activity of novel tetrahydrobenzo[4,5-b]thieno[3,2-c:5,6]pyrido[4,3-d]pyrimidin-4(3H)-ones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6713-6716.	1.0	13
80	Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 349-356.	1.1	138